---
kind: "section"
citation: "21 C.F.R. § 343.90"
title: "21"
number: "343.90"
heading: "Dissolution and drug release testing."
url: "https://uscodex.org/cfr/21/343.90"
---

# §343.90. Dissolution and drug release testing.

- (a) [Reserved]
- (b) **Aspirin capsules.** Aspirin capsules must meet the dissolution standard for aspirin capsules as contained in the United States Pharmacopeia (USP) 23 at page 132.
- (c) **Aspirin delayed-release capsules and aspirin delayed-release tablets.** Aspirin delayed-release capsules and aspirin delayed-release tablets must meet the drug release standard for aspirin delayed-release capsules and aspirin delayed-release tablets as contained in USP 23 at pages 133 and 136 respectively.
- (d) **Aspirin tablets.** Aspirin tablets must meet the dissolution standard for aspirin tablets as contained in USP 23 at page 134.
- (e) **Aspirin, alumina, and magnesia tablets.** Aspirin in combination with alumina and magnesia in a tablet dosage form must meet the dissolution standard for aspirin, alumina, and magnesia tablets as contained in USP 23 at page 138.
- (f) **Aspirin, alumina, and magnesium oxide tablets.** Aspirin in combination with alumina, and magnesium oxide in a tablet dosage form must meet the dissolution standard for aspirin, alumina, and magnesium tablets as contained in USP 23 at page 139.
- (g) **Aspirin effervescent tablets for oral solution.** Aspirin effervescent tablets for oral solution must meet the dissolution standard for aspirin effervescent tablets for oral solution as contained in USP 23 at page 137.
- (h) **Buffered aspirin tablets.** Buffered aspirin tablets must meet the dissolution standard for buffered aspirin tablets as contained in USP 23 at page 135.

## Notes

### Authority

Authority: 21 U.S.C. 321, 351, 352, 353, 355, 360, 371.

### Source

Source: 63 FR 56814, Oct. 23, 1998, unless otherwise noted.